Lung cancer with EGFR mutation is often associated pathological characteristics and good
responses to EGFR tyrosine kinase inhibitors (TKIs). However, certain types of rare EGFR …

Background Epidemiological surveys have suggested that lung cancer has inherited
susceptibility and shows familial aggregation. However, the distribution and prevalence of …

Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …

Objectives: To discover the incidence and characteristics of EGFR mutations in non-small
cell lung cancer (NSCLC) in a single, large cohort as a part of routine diagnostic …

Background: The detection of pro-oncogenic mutations such as mutations in the epidermal
growth factor receptor (EGFR) allowed the development of targeted therapies as inhibitor of …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

We aimed to reveal the true status of epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small cell lung cancer (NSCLC) after lung resections. EGFR …

Large‐scale genomic characterization of non‐small cell lung cancer (NSCLC) has revealed
several putative oncogenic driver mutations that may constitute druggable therapeutic …

Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …

Objective: To analyze the EGFR mutation profile of lung cancer patients in Yunnan, and to
provide evidence for clinical personalized treatment. Methods: Demographic and clinical …